Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Roundhill NVDA WeeklyPay ETF (NVDW) vs Pfizer Inc (PFE) Price & Performance

Roundhill NVDA WeeklyPay ETFTrade
Pfizer IncTrade

Price performance (Past 24H)

Key statistics

Roundhill NVDA WeeklyPay ETF vs Pfizer Inc — how do they compare? Roundhill NVDA WeeklyPay ETF trades at $37.11, while Pfizer Inc trades at $27.88 (market cap $158.39B). The key difference: Pfizer Inc pays a 6.19% dividend while Roundhill NVDA WeeklyPay ETF pays none, and Pfizer Inc is trading nearer its 52-week high, Roundhill NVDA WeeklyPay ETF nearer its low. Which is the better fit depends on your goals.

NVDWPFE
Sector
Income / Options OverlayHealth
52-Week High
$52.33$29.02
52-Week Low
$31.88$23.60
Market Cap
$158.39B
Volume
29,869,932
Enterprise Value
$209.89B
Dividend Yield
6.19%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Roundhill NVDA WeeklyPay ETF

NVDW (Roundhill NVDA WeeklyPay ETF) trades at $37.60, down 3.22% with a bullish technical signal from moving averages. The ETF provides leveraged exposure to Nvidia with weekly dividend payments, though key valuation ratios remain unavailable. Recent news highlights its high-yield income strategy tied to NVDA's performance, with payouts fluctuating based on underlying stock volatility.

The outlook depends heavily on Nvidia's continued earnings strength and AI market momentum. Key risks include leverage amplification during NVDA downturns and variable dividend sustainability. Investors seeking weekly income from tech exposure may find value, but must monitor NAV erosion risks amid sector volatility.

Pfizer Inc

Pfizer (PFE) trades at $27.78, down 2.36% today, with a consensus price target of $28.33 suggesting modest upside. The stock shows mixed technical signals with bullish moving averages but neutral oscillators. Recent earnings have consistently beaten expectations, though revenue declined from pandemic peaks. The company maintains strong cash flow generation and a solid dividend yield of approximately 3.1%.

Pfizer presents a value opportunity with reasonable valuation metrics and dividend stability, but faces headwinds from post-COVID revenue normalization and patent expirations. The company's pipeline progress in obesity and oncology could drive future growth, though execution risks remain. Analyst sentiment leans cautious with 59% hold ratings.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Roundhill NVDA WeeklyPay ETF

NVDW is an actively managed ETF that seeks to provide weekly distributions and returns equal to 1.2 times (120%) the calendar week performance of Nvidia (NVDA) common shares. It combines modest leverage with a high-frequency payout schedule, designed for investors who want amplified exposure to Nvidia alongside a consistent weekly income stream.

Read more on NVDW

About Pfizer Inc

Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.

Read more on PFE